Results from a phase 3 clinical indicate that the oral drug mitapivat is safe and effective for treating adults with pyruvate kinase deficiency, a genetic condition that causes red blood cell destruction. The trial’s results led to the drug’s approval by the U.S. Food and Drug Administration in February.
